vs

Side-by-side financial comparison of Taysha Gene Therapies, Inc. (TSHA) and Venu Holding Corp (VENU). Click either name above to swap in a different company.

Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.5M, roughly 1.2× Venu Holding Corp). Venu Holding Corp runs the higher net margin — -215.5% vs -507.8%, a 292.3% gap on every dollar of revenue.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.

Venu Holding Corporation ("Venu") is a publicly-traded American entertainment and hospitality company based in Colorado Springs, Colorado. Founded by JW Roth in 2017 as Notes Live, Venu designs, develops, manages and owns music venues and event spaces including amphitheaters, restaurants, and concert halls in midsize cities.

TSHA vs VENU — Head-to-Head

Bigger by revenue
TSHA
TSHA
1.2× larger
TSHA
$5.5M
$4.5M
VENU
Higher net margin
VENU
VENU
292.3% more per $
VENU
-215.5%
-507.8%
TSHA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
TSHA
TSHA
VENU
VENU
Revenue
$5.5M
$4.5M
Net Profit
$-27.9M
$-9.8M
Gross Margin
Operating Margin
-516.0%
-161.6%
Net Margin
-507.8%
-215.5%
Revenue YoY
171.3%
Net Profit YoY
-48.3%
EPS (diluted)
$-0.08
$-0.77

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TSHA
TSHA
VENU
VENU
Q4 25
$5.5M
$4.5M
Q3 25
$0
$5.4M
Q2 25
$2.0M
$4.5M
Q1 25
$2.3M
$3.5M
Q4 24
$2.0M
Q3 24
$1.8M
$5.5M
Q2 24
$1.1M
Q1 24
$3.4M
Net Profit
TSHA
TSHA
VENU
VENU
Q4 25
$-27.9M
$-9.8M
Q3 25
$-32.7M
$-6.4M
Q2 25
$-26.9M
$-12.3M
Q1 25
$-21.5M
$-18.1M
Q4 24
$-18.8M
Q3 24
$-25.5M
$-3.9M
Q2 24
$-20.9M
Q1 24
$-24.1M
Operating Margin
TSHA
TSHA
VENU
VENU
Q4 25
-516.0%
-161.6%
Q3 25
-185.2%
Q2 25
-1347.1%
-229.7%
Q1 25
-930.5%
-529.9%
Q4 24
-985.8%
Q3 24
-1448.4%
-67.4%
Q2 24
-1915.4%
Q1 24
-713.3%
Net Margin
TSHA
TSHA
VENU
VENU
Q4 25
-507.8%
-215.5%
Q3 25
-118.1%
Q2 25
-1353.6%
-274.2%
Q1 25
-935.2%
-516.2%
Q4 24
-929.0%
Q3 24
-1427.5%
-72.1%
Q2 24
-1882.0%
Q1 24
-705.4%
EPS (diluted)
TSHA
TSHA
VENU
VENU
Q4 25
$-0.08
$-0.77
Q3 25
$-0.09
$-0.15
Q2 25
$-0.09
$0.30
Q1 25
$-0.08
$-0.48
Q4 24
$-0.07
Q3 24
$-0.10
$-0.13
Q2 24
$-0.09
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TSHA
TSHA
VENU
VENU
Cash + ST InvestmentsLiquidity on hand
$319.8M
Total DebtLower is stronger
$58.9M
Stockholders' EquityBook value
$246.9M
$122.7M
Total Assets
$343.3M
$370.6M
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TSHA
TSHA
VENU
VENU
Q4 25
$319.8M
Q3 25
$297.3M
Q2 25
$312.8M
Q1 25
$116.6M
Q4 24
$139.0M
Q3 24
$157.7M
Q2 24
$172.7M
Q1 24
$124.0M
Total Debt
TSHA
TSHA
VENU
VENU
Q4 25
$58.9M
Q3 25
$58.9M
Q2 25
$44.8M
Q1 25
$54.7M
Q4 24
Q3 24
$22.8M
Q2 24
Q1 24
Stockholders' Equity
TSHA
TSHA
VENU
VENU
Q4 25
$246.9M
$122.7M
Q3 25
$219.0M
$121.2M
Q2 25
$248.7M
$90.2M
Q1 25
$55.1M
$78.4M
Q4 24
$71.5M
Q3 24
$88.8M
$79.4M
Q2 24
$108.9M
Q1 24
$53.8M
Total Assets
TSHA
TSHA
VENU
VENU
Q4 25
$343.3M
$370.6M
Q3 25
$316.6M
$314.8M
Q2 25
$333.3M
$242.0M
Q1 25
$138.4M
$212.9M
Q4 24
$160.4M
Q3 24
$180.2M
$166.6M
Q2 24
$200.4M
Q1 24
$153.0M
Debt / Equity
TSHA
TSHA
VENU
VENU
Q4 25
0.48×
Q3 25
0.49×
Q2 25
0.50×
Q1 25
0.70×
Q4 24
Q3 24
0.29×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TSHA
TSHA
VENU
VENU
Operating Cash FlowLast quarter
$-26.7M
$12.8M
Free Cash FlowOCF − Capex
$-52.4M
FCF MarginFCF / Revenue
-1157.6%
Capex IntensityCapex / Revenue
1441.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-134.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TSHA
TSHA
VENU
VENU
Q4 25
$-26.7M
$12.8M
Q3 25
$-24.2M
$6.3M
Q2 25
$-20.2M
$-2.4M
Q1 25
$-22.0M
$-9.0M
Q4 24
$-18.3M
Q3 24
$-21.6M
Q2 24
$-21.5M
Q1 24
$-19.8M
Free Cash Flow
TSHA
TSHA
VENU
VENU
Q4 25
$-52.4M
Q3 25
$-24.3M
$-32.9M
Q2 25
$-17.6M
Q1 25
$-31.1M
Q4 24
$-18.3M
Q3 24
$-21.6M
Q2 24
$-21.7M
Q1 24
$-19.9M
FCF Margin
TSHA
TSHA
VENU
VENU
Q4 25
-1157.6%
Q3 25
-611.3%
Q2 25
-392.4%
Q1 25
-888.4%
Q4 24
-905.5%
Q3 24
-1210.9%
Q2 24
-1951.9%
Q1 24
-584.5%
Capex Intensity
TSHA
TSHA
VENU
VENU
Q4 25
1441.2%
Q3 25
728.3%
Q2 25
337.9%
Q1 25
630.1%
Q4 24
0.1%
Q3 24
2.0%
Q2 24
18.1%
Q1 24
4.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TSHA
TSHA

Segment breakdown not available.

VENU
VENU

Food And Beverage$2.9M64%
Other$1.6M36%

Related Comparisons